Sprint Bioscience AB (ST:SPRINT) — Market Cap & Net Worth
Market Cap & Net Worth: Sprint Bioscience AB (SPRINT)
Sprint Bioscience AB (ST:SPRINT) has a market capitalization of $33.50 Million (Skr311.27 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #23483 globally and #444 in its home market, demonstrating a 7.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sprint Bioscience AB's stock price Skr2.95 by its total outstanding shares 105515538 (105.52 Million). Also see Sprint Bioscience AB (SPRINT) total assets for a full breakdown of the balance sheet.
Sprint Bioscience AB Market Cap History: 2015 to 2026
Sprint Bioscience AB's market capitalization history from 2015 to 2026. Data shows change from $360.03 Million to $33.50 Million (-19.64% CAGR). Also see Sprint Bioscience AB cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Sprint Bioscience AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.23 Billion | 0.22% | #78 of 281 |
Weight: Sprint Bioscience AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sprint Bioscience AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sprint Bioscience AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Sprint Bioscience AB stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.10x
Sprint Bioscience AB's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.18x
Sprint Bioscience AB's market cap is 0.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $264.30 Million | $34.99 Million | $4.54 Million | 7.55x | 58.21x |
| 2017 | $193.14 Million | $23.97 Million | -$10.66 Million | 8.06x | N/A |
| 2018 | $175.35 Million | $17.94 Million | -$22.22 Million | 9.78x | N/A |
| 2019 | $103.35 Million | $33.54 Million | -$22.74 Million | 3.08x | N/A |
| 2020 | $70.69 Million | $16.89 Million | -$46.23 Million | 4.19x | N/A |
| 2021 | $46.34 Million | $35.11 Million | -$25.35 Million | 1.32x | N/A |
| 2022 | $6.28 Million | $83.00K | -$60.17 Million | 75.66x | N/A |
| 2023 | $19.70 Million | $50.48 Million | -$438.00K | 0.39x | N/A |
| 2024 | $17.96 Million | $65.64 Million | -$18.28 Million | 0.27x | N/A |
| 2025 | $16.69 Million | $167.17 Million | $91.74 Million | 0.10x | 0.18x |
Competitor Companies of SPRINT by Market Capitalization
Companies near Sprint Bioscience AB in the global market cap rankings as of September 19, 2026. Review SPRINT goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sprint Bioscience AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Sprint Bioscience AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Sprint Bioscience AB's market cap moved from $360.03 Million to $ 33.50 Million, with a yearly change of -19.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr33.50 Million | +100.68% |
| 2025 | Skr16.69 Million | -7.08% |
| 2024 | Skr17.96 Million | -8.82% |
| 2023 | Skr19.70 Million | +213.74% |
| 2022 | Skr6.28 Million | -86.45% |
| 2021 | Skr46.34 Million | -34.44% |
| 2020 | Skr70.69 Million | -31.60% |
| 2019 | Skr103.35 Million | -41.06% |
| 2018 | Skr175.35 Million | -9.21% |
| 2017 | Skr193.14 Million | -26.92% |
| 2016 | Skr264.30 Million | -26.59% |
| 2015 | Skr360.03 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Sprint Bioscience AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.50 Million USD |
| MoneyControl | $33.50 Million USD |
| MarketWatch | $33.50 Million USD |
| marketcap.company | $33.50 Million USD |
| Reuters | $33.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a d… Read more